Boji Medical: Signed the "Technology Transfer Agreement" with a total transfer fee of 14 million yuan

Boji Pharmaceutical Announcement: The company has signed a “Technology Transfer Contract” with Chengdu Push Pharmaceutical Co., Ltd. Under the contract, the company will transfer to Push Pharmaceutical the current-stage technological achievements of its “Fluconazole Ear Drops (FCZR)” (“FCZR”). The total technology transfer fees under the contract amount to RMB 14.00 million. The signing of this contract does not require approval by the company’s board of directors and shareholders’ meeting, and it does not constitute a related-party transaction or a major asset restructuring. Push Pharmaceutical is not a person subject to enforcement for breach of trust, and there is no related-party relationship between Push Pharmaceutical and the company.

In the most recent three accounting years, Push Pharmaceutical has also signed supplementary agreements with the company for preclinical research projects for “Pilocarpine Hydrochloride Eye Drops” and “Diquafosol Sodium Eye Drops.” The total contract amount of these supplementary agreements is RMB 2.7918 million. The company recognizes revenue based on the progress of the projects. The signing of the supplementary agreements will not have a material impact on the company’s operating performance for the current year.